Artificial Intelligence-assisted System in Colonoscopy

Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · May 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of artificial intelligence (AI) to help detect adenoma colon polyps during colonoscopy procedures. Colon polyps are growths on the lining of the colon that can sometimes lead to cancer, so finding and removing them is very important. The researchers want to see if using AI can improve the rate at which these polyps are detected compared to traditional methods. This study will take place in multiple centers and is designed to gather real-world data about how effective AI can be in enhancing the quality of colonoscopies.

To participate, you must be over 50 years old and need a diagnostic or screening colonoscopy. You'll need to voluntarily agree to join the study and follow the procedures. However, certain individuals, such as those with specific medical conditions or those already involved in other clinical trials, may not be eligible. If you join, you can expect to undergo a standard colonoscopy while the research team collects information on how well the AI system works in detecting polyps. This trial is currently looking for participants, and your involvement could help improve colon cancer screening methods in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age \> 50 years old;
• • 2. required diagnostic colonoscopy, screening colonoscopy, or follow-up colonoscopy;
• • 3. voluntarily sign informed consent;
• • 4. Commitment to abide by the study procedures and cooperate with the implementation of the whole process of the study.
• Exclusion Criteria:
• • 1. have participated in other clinical trials, signed informed consent and are in the follow-up period of other clinical trials;
• • 2. known polyposis syndrome patients;
• • 3. patients with known IBD;
• • 4. patients considered by the investigators to be unsuitable or unable to undergo complete digestive endoscopy and related examinations;
• • 5. high-risk diseases or other special conditions considered by the investigator to be unsuitable for clinical trial participation.